Viewray (NASDAQ: VRAY) and Dynatronics (NASDAQ:DYNT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.
Risk and Volatility
Viewray has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Comparatively, Dynatronics has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500.
This table compares Viewray and Dynatronics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
51.2% of Viewray shares are owned by institutional investors. Comparatively, 18.2% of Dynatronics shares are owned by institutional investors. 62.8% of Viewray shares are owned by insiders. Comparatively, 51.8% of Dynatronics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Viewray and Dynatronics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Viewray||$22.24 million||27.03||-$50.63 million||($1.13)||-7.88|
|Dynatronics||$35.76 million||0.60||-$1.86 million||($1.15)||-2.37|
Dynatronics has higher revenue and earnings than Viewray. Viewray is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations and price targets for Viewray and Dynatronics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Viewray presently has a consensus target price of $11.58, suggesting a potential upside of 30.15%. Given Viewray’s higher probable upside, research analysts clearly believe Viewray is more favorable than Dynatronics.
Viewray beats Dynatronics on 8 of the 12 factors compared between the two stocks.
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Dynatronics Corporation is a manufacturer and distributor of physical medicine products. The Company’s products include a line of medical equipment for physical medicine applications, including therapy devices, medical supplies and soft goods, treatment tables and rehabilitation equipment. Its products are used by physical therapists, chiropractors, sports medicine practitioners, podiatrists, physicians and other physical medicine professionals. Its physical medicine products include therapeutic modalities, such as Dynatron Solaris, including electrotherapy and thermal therapy, and 25 Series, including electrotherapy and ultrasound; manufactured capital products, including traction systems and wood furniture; manufactured supplies, including cold packs, straps, wedges, bolsters and mats; distributed capital products, including hydrotherapy, weight training equipment and pilates, and distributed supplies, including clinical accessories, sports med and taping products, lotions and gels.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.